Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/714
Type: Artigo de periódico
Title: mRNA Expression Profile of Multidrug Resistance Genes in Childhood Acute Lymphoblastic Leukemia. Low Expression Levels Associated With a Higher Risk of Toxic Death
Author: CORTEZ, Maria A. A.
SCRIDELI, Carlos A.
YUNES, Jose A.
VALERA, Elvis T.
TOLEDO, Silvia R. C.
PAVONI-FERREIRA, Patricia C. B.
LEE, Maria L. M.
PETRILLI, Antonio S.
BRANDALISE, Silvia R.
TONE, Luiz G.
Abstract: Background. Increased activity of multidrug resistance (MDR) genes has been associated with treatment failure in acute leukemias, although with controversial reports. The objective of the present study was to assess the expression profile of the genes related to MDR: ABCB1, ABCC1, ABCC3, ABCC2, and LRP/MVP in terms of the clinical and biological variable and the survival of children with acute lymphoblastic leukemia (ALL). Procedure. The levels of mRNA expression of the drug resistance genes ABCB1, ABCC1, ABCC3, ABCG2, and LRP/MVP were analyzed by quantitative real-time PCR using the median Values as cut-off points, in consecutive samples from 140 children with ALL at diagnosis. Results. Expression levels of the ABCG2 gene in the patient group as a whole (P=0.05) and of the ABCG2 and ABCC1 genes in patients classified as being at high risk were associated with higher rates of 5-year event-free survival (EFS) (P=0.04 and P=0.01). Expression levels of the ABCG2 gene below the median were associated with a greater chance of death related to treatment toxicity for the patient group as a whole (P=0.009) and expression levels below the median of the ABCG2 and ABCC1 genes were associated with a greater chance of death due to treatment toxicity for the high-risk group (P=0.02 and P=0.03, respectively). Conclusion. The present data suggest a low participation of the drug efflux genes in treatment failure in patients with childhood ALL. However, the low expression of some of these genes may be associated with a higher death risk related to treatment toxicity. Pediatr Blood Cancer 2009;53:996-1004. (C) 2009 Wiley-Liss, Inc.
Subject: acute lymphoblastic leukemia
cancer biology
multidrug resistance
Country: Estados Unidos
Editor: WILEY-LISS
Citation: PEDIATRIC BLOOD & CANCER, v.53, n.6, p.996-1004, 2009
Rights: fechado
Identifier DOI: 10.1002/pbc.22220
Address: http://dx.doi.org/10.1002/pbc.22220
http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&UT=000270440900016&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord
Date Issue: 2009
Appears in Collections:FCM - Artigos e Materiais de Revistas Científicas

Files in This Item:
File Description SizeFormat 
art_CORTEZ_mRNA_Expression_Profile_of_Multidrug_Resistance_Genes_2009.pdfpublished version227.55 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.